Neuphoria Therapeutics (NEUP) Invested Capital (2020 - 2025)
Historic Invested Capital for Neuphoria Therapeutics (NEUP) over the last 6 years, with Q4 2025 value amounting to $29.7 million.
- Neuphoria Therapeutics' Invested Capital rose 11603.75% to $29.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $29.7 million, marking a year-over-year increase of 11603.75%. This contributed to the annual value of $19.0 million for FY2025, which is N/A changed from last year.
- As of Q4 2025, Neuphoria Therapeutics' Invested Capital stood at $29.7 million, which was up 11603.75% from $12.5 million recorded in Q3 2025.
- Neuphoria Therapeutics' Invested Capital's 5-year high stood at $43.9 million during Q4 2021, with a 5-year trough of $12.5 million in Q3 2025.
- Moreover, its 5-year median value for Invested Capital was $22.2 million (2023), whereas its average is $25.0 million.
- In the last 5 years, Neuphoria Therapeutics' Invested Capital crashed by 4565.24% in 2023 and then skyrocketed by 11603.75% in 2025.
- Neuphoria Therapeutics' Invested Capital (Quarter) stood at $43.9 million in 2021, then fell by 7.17% to $40.8 million in 2022, then tumbled by 45.65% to $22.2 million in 2023, then tumbled by 37.95% to $13.7 million in 2024, then skyrocketed by 116.04% to $29.7 million in 2025.
- Its Invested Capital stands at $29.7 million for Q4 2025, versus $12.5 million for Q3 2025 and $19.0 million for Q2 2025.